Lebrikizumab Completed Phase 2 Trials for Atopic Dermatitis (AD) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03443024A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis
NCT02340234A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
NCT02465606A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis